ifosfamide has been researched along with Acute Kidney Failure in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 9.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
| "Ifosfamide is metabolized into chloroacetaldehyde, which can cause acute kidney injury." | 8.12 | Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report. ( Boskabadi, J; Salehifar, E; Yousefi-Mazhin, E, 2022) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 7.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma." | 5.07 | Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994) |
| "Ifosfamide is metabolized into chloroacetaldehyde, which can cause acute kidney injury." | 4.12 | Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report. ( Boskabadi, J; Salehifar, E; Yousefi-Mazhin, E, 2022) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 3.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| " Kidney adverse effects may include acute kidney injury (via tubular injury, tubulointerstitial nephritis, glomerular disease and thrombotic microangiopathy), long-term kidney function loss and CKD, and electrolyte disturbances." | 2.72 | Conventional Chemotherapy Nephrotoxicity. ( Daher, A; Gupta, S; Kitchlu, A; Portales-Castillo, I, 2021) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| "Ifosfamide (IFO) is an alkylating agent administered against different types of malignancies." | 1.56 | The Nephroprotective Role of Carnosine Against Ifosfamide-Induced Renal Injury and Electrolytes Imbalance is Mediated Via the Regulation of Mitochondrial Function and Alleviation of Oxidative Stress. ( Farshad, O; Ghanbarinejad, V; Heidari, R; Ilkhaninasab, F; Khadijeh, M; Moezi, L; Mohammadi, HR; Negar, A; Ommati, MM; Zahra, M, 2020) |
| "Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities." | 1.48 | Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. ( Harel-Sterling, M; Hessey, E; Huynh, L; McMahon, KR; Pizzi, M; Zappitelli, M, 2018) |
| "Ifosfamide (IFO) is a highly effective chemotherapeutic agent for treating a variety of pediatric solid tumors." | 1.42 | Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity. ( El-Desoky, KI; El-Sisi, Ael-D; El-Syaad, ME; Moussa, EA, 2015) |
| "Ifosfamide is an alkylating agent used to treat different types of malignancies including lymphomas, sarcomas and germinal cell tumors." | 1.39 | Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. ( Bhardwaj, H; Cherry, MA; Hopps, S; Pant, S; Srour, S, 2013) |
| "Subsequently, acute renal failure (ARF) occurred dose-dependently." | 1.34 | Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. ( Lu, H; Zhang, J, 2007) |
| " Since ICE has substantial activity in a number of malignancies, but significant renal morbidity, real-time pharmacokinetic-guided dosing may reduce treatment-related toxicity." | 1.29 | High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. ( Andersen, J; Antman, K; Elias, A; Frel, E; Holden, S; Rosowsky, A; Schwartz, G; Tretyakov, O; Wheeler, C; Wright, JE, 1995) |
| "A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion." | 1.28 | Severe renal failure following high-dose ifosfamide and mesna. ( de Jong, PE; Elema, JD; Mulder, NH; Willemse, PH, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.34) | 18.7374 |
| 1990's | 7 (24.14) | 18.2507 |
| 2000's | 7 (24.14) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, S | 1 |
| Portales-Castillo, I | 1 |
| Daher, A | 1 |
| Kitchlu, A | 1 |
| Boskabadi, J | 1 |
| Yousefi-Mazhin, E | 1 |
| Salehifar, E | 1 |
| Ommati, MM | 1 |
| Farshad, O | 1 |
| Ghanbarinejad, V | 1 |
| Mohammadi, HR | 1 |
| Khadijeh, M | 1 |
| Negar, A | 1 |
| Zahra, M | 1 |
| Ilkhaninasab, F | 1 |
| Moezi, L | 1 |
| Heidari, R | 1 |
| Sterling, M | 1 |
| Al-Ismaili, Z | 1 |
| McMahon, KR | 2 |
| Piccioni, M | 1 |
| Pizzi, M | 2 |
| Mottes, T | 1 |
| Lands, LC | 1 |
| Abish, S | 1 |
| Fleming, AJ | 1 |
| Bennett, MR | 1 |
| Palijan, A | 1 |
| Devarajan, P | 1 |
| Goldstein, SL | 1 |
| O'Brien, MM | 1 |
| Zappitelli, M | 2 |
| Harel-Sterling, M | 1 |
| Huynh, L | 1 |
| Hessey, E | 1 |
| Nishimura, H | 1 |
| Enokida, H | 1 |
| Nagano, S | 1 |
| Yokouchi, M | 1 |
| Hayami, H | 1 |
| Komiya, S | 1 |
| Nakagawa, M | 1 |
| Cheah, CY | 1 |
| Herbert, KE | 1 |
| O'Rourke, K | 1 |
| Kennedy, GA | 1 |
| George, A | 1 |
| Fedele, PL | 1 |
| Gilbertson, M | 1 |
| Tan, SY | 1 |
| Ritchie, DS | 1 |
| Opat, SS | 1 |
| Prince, HM | 1 |
| Dickinson, M | 1 |
| Burbury, K | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Tam, CS | 1 |
| Westerman, DA | 1 |
| Carney, DA | 1 |
| Harrison, SJ | 1 |
| Seymour, JF | 1 |
| Beyzadeoglu, M | 1 |
| Arpaci, F | 1 |
| Surenkok, S | 1 |
| Ozyigit, G | 1 |
| Oysul, K | 1 |
| Caglar, K | 1 |
| Ataergin, S | 1 |
| Yenicesu, M | 1 |
| Kaya, A | 1 |
| Perazella, MA | 1 |
| Moeckel, GW | 1 |
| Hanly, LN | 1 |
| Chen, N | 1 |
| Aleksa, K | 1 |
| Cutler, M | 1 |
| Bajcetic, M | 1 |
| Palassery, R | 1 |
| Regueira, O | 1 |
| Turner, C | 1 |
| Baw, B | 1 |
| Malkin, B | 1 |
| Freeman, D | 1 |
| Rieder, MJ | 1 |
| Vasylyeva, TL | 1 |
| Koren, G | 1 |
| Farry, JK | 1 |
| Flombaum, CD | 1 |
| Latcha, S | 1 |
| Cherry, MA | 1 |
| Bhardwaj, H | 1 |
| Hopps, S | 1 |
| Srour, S | 1 |
| Pant, S | 1 |
| El-Sisi, Ael-D | 1 |
| El-Syaad, ME | 1 |
| El-Desoky, KI | 1 |
| Moussa, EA | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Ferrari, S | 1 |
| Pieretti, F | 1 |
| Verri, E | 1 |
| Tolentinis, L | 1 |
| Cesari, M | 1 |
| Versari, M | 1 |
| Zolezzi, C | 1 |
| Lamanna, G | 1 |
| Bacci, G | 1 |
| Escobosa Sánchez, OM | 1 |
| Herrero Hernández, A | 1 |
| Ortega Acosta, MJ | 1 |
| Camacho Alonso, J | 1 |
| Milano Manso, G | 1 |
| Acha García, T | 1 |
| Nonomura, N | 1 |
| Oka, D | 1 |
| Nishimura, K | 1 |
| Nakayama, M | 1 |
| Inoue, H | 1 |
| Mizutani, Y | 1 |
| Miki, T | 1 |
| Okuyama, A | 1 |
| Zhang, J | 1 |
| Lu, H | 1 |
| Kreusser, W | 1 |
| Herrmann, R | 1 |
| Tschöpe, W | 1 |
| Ritz, E | 1 |
| Wright, JE | 1 |
| Elias, A | 1 |
| Tretyakov, O | 1 |
| Holden, S | 1 |
| Andersen, J | 1 |
| Wheeler, C | 1 |
| Schwartz, G | 1 |
| Antman, K | 1 |
| Rosowsky, A | 1 |
| Frel, E | 1 |
| Raney, B | 1 |
| Ensign, LG | 1 |
| Foreman, J | 1 |
| Khan, F | 1 |
| Newton, W | 1 |
| Ortega, J | 1 |
| Ragab, A | 1 |
| Wharam, M | 1 |
| Wiener, E | 1 |
| Maurer, H | 1 |
| Choi, JH | 1 |
| Choi, GB | 1 |
| Shim, KN | 1 |
| Sung, SH | 1 |
| Han, WS | 1 |
| Baek, SY | 1 |
| Beyer, J | 1 |
| Rick, O | 1 |
| Weinknecht, S | 1 |
| Kingreen, D | 1 |
| Lenz, K | 1 |
| Siegert, W | 1 |
| Krämer, A | 1 |
| Andrassy, K | 1 |
| Ho, AD | 1 |
| Suarez, A | 1 |
| McDowell, H | 1 |
| Niaudet, P | 1 |
| Comoy, E | 1 |
| Flamant, F | 1 |
| Markman, M | 1 |
| Hakes, T | 1 |
| Reichman, B | 1 |
| Lewis, JL | 1 |
| Rubin, S | 1 |
| Jones, W | 1 |
| Almadrones, L | 1 |
| Pizzuto, F | 1 |
| Hoskins, W | 1 |
| Honda, R | 1 |
| Fujita, A | 1 |
| Inoue, Y | 1 |
| Asakawa, M | 1 |
| Suzuki, A | 1 |
| Willemse, PH | 1 |
| de Jong, PE | 1 |
| Elema, JD | 1 |
| Mulder, NH | 1 |
| Cantwell, BM | 1 |
| Carmichael, J | 1 |
| Mannix, KA | 1 |
| Harris, AL | 1 |
3 reviews available for ifosfamide and Acute Kidney Failure
| Article | Year |
|---|---|
Conventional Chemotherapy Nephrotoxicity.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Ifosfamide | 2021 |
Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Cisplatin; Diphosphonates; Humans; Ifosfamide; Kidney Gl | 2010 |
Nephrological complications of cancer therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Humans; Ifosfamide; Kidney; | 1982 |
7 trials available for ifosfamide and Acute Kidney Failure
| Article | Year |
|---|---|
Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Child; | 2017 |
N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics.
Topics: Acetaminophen; Acetylcysteine; Acute Kidney Injury; Adolescent; Analgesics, Non-Narcotic; Animals; A | 2012 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; An | 2007 |
Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Topics: Acute Kidney Injury; Adolescent; Adult; Chemotherapy, Adjuvant; Child; Child, Preschool; Creatinine; | 1994 |
Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 1997 |
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Topics: Acute Kidney Injury; Adult; Aged; Carcinoma; Drug Evaluation; Drug Resistance; Female; Humans; Ifosf | 1992 |
19 other studies available for ifosfamide and Acute Kidney Failure
| Article | Year |
|---|---|
Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report.
Topics: Acetylcysteine; Acute Kidney Injury; Creatinine; Female; Humans; Ifosfamide; Leiomyosarcoma; Mesna; | 2022 |
The Nephroprotective Role of Carnosine Against Ifosfamide-Induced Renal Injury and Electrolytes Imbalance is Mediated Via the Regulation of Mitochondrial Function and Alleviation of Oxidative Stress.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Carnosine; Disease Mo | 2020 |
Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2018 |
Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Hemodiaf | 2014 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibo | 2014 |
Acute renal toxicity of 2 conditioning regimens in patients undergoing autologous peripheral blood stem-cell transplantation. Total body irradiation-cyclophosphamide versus ifosfamide, carboplatin, etoposide.
Topics: Acute Kidney Injury; Adult; Carboplatin; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Hum | 2008 |
Long term renal toxicity of ifosfamide in adult patients--5 year data.
Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Carbop | 2012 |
Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Ly | 2013 |
Protective effects of alpha lipoic acid versus N-acetylcysteine on ifosfamide-induced nephrotoxicity.
Topics: Acetylcysteine; Acute Kidney Injury; Animals; Antioxidants; Glutathione; Ifosfamide; Kidney; Lipid P | 2015 |
Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2005 |
Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplati | 2006 |
Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Auranofin; | 2007 |
High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 1995 |
Bilateral primary renal non-Hodgkin's lymphoma presenting with acute renal failure: successful treatment with systemic chemotherapy.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophospham | 1997 |
Renal failure after bone marrow transplantation.
Topics: Acute Kidney Injury; Bone Marrow Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Kidn | 2001 |
Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 1991 |
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sma | 1990 |
Severe renal failure following high-dose ifosfamide and mesna.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma; Dose-Respons | 1989 |
Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; H | 1989 |